Address: PO Box 781247
Sandton 2146
Gauteng,South Africa
Tel: +27 11 883 5630
Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions, but importantly, to improve the quality of life for patients with a variety of acute and chronic illnesses. We have a long-standing tradition of building high quality relationships based on the highest standards, with patients, physicians, employees, partners and other key stakeholders.
In the last fifteen years, we have focused on expanding our pan-European infrastructure, and have moved to strengthen the Research & Development base of the company.
In addition to developing, manufacturing and marketing our own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and commercialisation of innovative pharmaceutical products across Europe. We value our development partnerships as, together with our own in-house product development, they support our growth ambitions and will help to facilitate our continued business expansion.
We have the resources to bring products to market on a pan-European or single country basis by combining sales and marketing expertise with all development, clinical research, product registration or manufacturing resources that our partners require.
In the years ahead, Norgine will continue to implement this successful strategy, building on our established infrastructure, strengthening our pan-European presence and collaborating with like-minded companies and organisations. By consolidating our successes, we can ensure we meet the challenges of an exciting future.
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the…
Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions,…
Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that…
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
In a notable first, following successful pilot immunisation programmes in Ghana, Kenya and Malawi, the World Health Organization (WHO) has recommended that the RTS,S malaria vaccine be rolled out across…
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials…
With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African…
The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer…
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share…
As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr Benjamin Pretorius, managing director at ERADA Technology Alliance, warns that diversions…
The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a Covid-19 drug, in South Africa this month. The company’s priority is ensuring access…
See our Cookie Privacy Policy Here
